Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348203 · ClinicalTrials.gov registry record · Phase 2
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02348203: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02348203 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02348203, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Aspirin
- OTHER Placebo Administration
- DRUG Zileuton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2016-01-13 |
| Est. Completion | 2021-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348203
The ClinicalTrials.gov registry entry for NCT02348203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02348203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348203 about?
NCT02348203 is a clinical study titled "Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers". This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.
What is the current status of trial NCT02348203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2016-01-13. Estimated completion is 2021-03-09.
What interventions are being tested in trial NCT02348203?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Aspirin (DRUG), Placebo Administration (OTHER), Zileuton (DRUG).
Who is sponsoring clinical trial NCT02348203?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.